Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vanadis Diagnostics operates within the Biotechnology & Pharmaceuticals technology area. The company's current prosecution profile includes 1 pending office action. This action is distributed across 1 distinct examiner and 1 distinct art unit. The presence of 1 distinct art unit suggests that the company's current filings are focused on a specific technical niche. This narrow scope of examination can lead to a more predictable prosecution process as it involves only 1 administrative unit at the USPTO.
The busiest examiner for Vanadis Diagnostics is POHNERT, STEVEN C, who is currently managing 1 busiest examiner pending office action. This examiner is responsible for the 1 pending office action that represents the company's total current prosecution activity. As a result, the outcome of the company's pending patent application is subject to the review of POHNERT, STEVEN C. Practitioners should focus their efforts on meeting the specific criteria set by this examiner. The 1 pending office action indicates a focused and streamlined phase of portfolio growth in the diagnostic sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16683763 | Multiplex Detection of Nucleic Acids | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16683763 | Multiplex Detection of Nucleic Acids | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16683763 | Multiplex Detection of Nucleic Acids | POHNERT, STEVEN C | 1683 | §101§103§112DP | Non-Final OA | — | Pending | Nov 14, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVanadis Diagnostics has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Steven C Pohnert has the most, with 1 of Vanadis Diagnostics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.